3.5 Impact of drugs on clinical outcomes
Considering the impact of treatment after infection with sars-cov-2 in
patients with ARDs on clinical outcomes, we conducted a subgroup
analysis. Without considering the proportion of patients using drugs,
regression analysis showed that ARD patients using GC had a higher
hospitalization rate of COVID-19(regression coefficient:0.484,
95%confidence interval:0.146-0.822, P=0.006), and using bDMARDs had a
lower ICU admission rate of COVID-19(regression coefficient:-0.156,
95%confidence interval:-0.260 - -0.051, P=0.006). The clinical outcomes
of ARD patients infected with COVID-19 who have used anti-rheumatic
drugs are shown in Supplementary Material Figure p11 and Figure p12.
From the perspective of major drugs, the hospitalization rates of ARD
patients using GC, bDMARDs, csDMARDs, and anti-TNF therapy were
0.703(95%CI:0.449-0.910), 0.216(95%CI:0.147-0.286),
0.607(95%CI:0.450-0.755) and 0.271(95%CI:0.132-0.409)(Figure 5).
Interestingly, the hospitalization rates of GC and csDMARD patients were
higher than the total rate, and patients with bDMARDs and anti-TNF
therapy were lower hospitalization than total cases. However, regression
analysis showed that regardless of whether the patients mainly used GC
or bDMARDs or csDMARDs or anti-TNF treatment, these treatment regimens
had no effect on the hospitalization rate of patients with
COVID-19(Figure p13).